Endothelial cells as target for antiphospholipid antibodies

Human polyclonal and monoclonal anti-β2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation

N. Del Papa, L. Guidali, A. Sala, C. Buccellati, M. A. Khamashta, K. Ichikawa, T. Koike, G. Balestrieri, A. Tincani, G. R V Hughes, P. L. Meroni

Research output: Contribution to journalArticle

253 Citations (Scopus)

Abstract

Objective. To investigate the ability of human anti-β2-glycoprotein I (anti-β2GPI) antibodies to recognize the cofactor adherent on endothelial cells (EC) and to modulate endothelial functions. Methods. Six human affinity-purified polyclonal anti-β2GPI IgG and 2 IgM monoclonal antibodies (MAb) were obtained from patients with the antiphospholipid syndrome. The antibodies were tested for their ability to 1) bind to endothelial monolayers through the adherent β2GPI and 2) modulate endothelial adhesion molecule expression and interleukin-6 (IL-6) and 6-keto-prostaglandin F(1α) (6-keto- PGF(1α)) secretion. Results. The affinity-purified IgG and the MAb with anti-β2GPI activity, but not the respective controls, displayed EC binding, which declined on cells incubated in serum-free medium and was restored in a dose-dependent manner by exogenous human β2GPI. After EC binding, both polyclonal and monoclonal antibodies up-regulated adhesion molecule expression. Anti-β2GPI MAb also significantly increased IL-6 and 6-keto- PGF(1α) secretion. Conclusion. These findings support the hypothesis that anti-β2GPI antibodies bind and activate EC through the adherent cofactor β2GPI, likely leading to a procoagulant state.

Original languageEnglish
Pages (from-to)551-561
Number of pages11
JournalArthritis and Rheumatism
Volume40
Issue number3
DOIs
Publication statusPublished - 1997

Fingerprint

Antiphospholipid Antibodies
Glycoproteins
Prostaglandins F
Endothelial Cells
Monoclonal Antibodies
Antibodies
Interleukin-6
Immunoglobulin G
Antiphospholipid Syndrome
Serum-Free Culture Media
Immunoglobulin M
In Vitro Techniques

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Endothelial cells as target for antiphospholipid antibodies : Human polyclonal and monoclonal anti-β2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation. / Del Papa, N.; Guidali, L.; Sala, A.; Buccellati, C.; Khamashta, M. A.; Ichikawa, K.; Koike, T.; Balestrieri, G.; Tincani, A.; Hughes, G. R V; Meroni, P. L.

In: Arthritis and Rheumatism, Vol. 40, No. 3, 1997, p. 551-561.

Research output: Contribution to journalArticle

Del Papa, N. ; Guidali, L. ; Sala, A. ; Buccellati, C. ; Khamashta, M. A. ; Ichikawa, K. ; Koike, T. ; Balestrieri, G. ; Tincani, A. ; Hughes, G. R V ; Meroni, P. L. / Endothelial cells as target for antiphospholipid antibodies : Human polyclonal and monoclonal anti-β2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation. In: Arthritis and Rheumatism. 1997 ; Vol. 40, No. 3. pp. 551-561.
@article{ee22210508a84568a5d1cd06b62bad47,
title = "Endothelial cells as target for antiphospholipid antibodies: Human polyclonal and monoclonal anti-β2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation",
abstract = "Objective. To investigate the ability of human anti-β2-glycoprotein I (anti-β2GPI) antibodies to recognize the cofactor adherent on endothelial cells (EC) and to modulate endothelial functions. Methods. Six human affinity-purified polyclonal anti-β2GPI IgG and 2 IgM monoclonal antibodies (MAb) were obtained from patients with the antiphospholipid syndrome. The antibodies were tested for their ability to 1) bind to endothelial monolayers through the adherent β2GPI and 2) modulate endothelial adhesion molecule expression and interleukin-6 (IL-6) and 6-keto-prostaglandin F(1α) (6-keto- PGF(1α)) secretion. Results. The affinity-purified IgG and the MAb with anti-β2GPI activity, but not the respective controls, displayed EC binding, which declined on cells incubated in serum-free medium and was restored in a dose-dependent manner by exogenous human β2GPI. After EC binding, both polyclonal and monoclonal antibodies up-regulated adhesion molecule expression. Anti-β2GPI MAb also significantly increased IL-6 and 6-keto- PGF(1α) secretion. Conclusion. These findings support the hypothesis that anti-β2GPI antibodies bind and activate EC through the adherent cofactor β2GPI, likely leading to a procoagulant state.",
author = "{Del Papa}, N. and L. Guidali and A. Sala and C. Buccellati and Khamashta, {M. A.} and K. Ichikawa and T. Koike and G. Balestrieri and A. Tincani and Hughes, {G. R V} and Meroni, {P. L.}",
year = "1997",
doi = "10.1002/art.1780400322",
language = "English",
volume = "40",
pages = "551--561",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Endothelial cells as target for antiphospholipid antibodies

T2 - Human polyclonal and monoclonal anti-β2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation

AU - Del Papa, N.

AU - Guidali, L.

AU - Sala, A.

AU - Buccellati, C.

AU - Khamashta, M. A.

AU - Ichikawa, K.

AU - Koike, T.

AU - Balestrieri, G.

AU - Tincani, A.

AU - Hughes, G. R V

AU - Meroni, P. L.

PY - 1997

Y1 - 1997

N2 - Objective. To investigate the ability of human anti-β2-glycoprotein I (anti-β2GPI) antibodies to recognize the cofactor adherent on endothelial cells (EC) and to modulate endothelial functions. Methods. Six human affinity-purified polyclonal anti-β2GPI IgG and 2 IgM monoclonal antibodies (MAb) were obtained from patients with the antiphospholipid syndrome. The antibodies were tested for their ability to 1) bind to endothelial monolayers through the adherent β2GPI and 2) modulate endothelial adhesion molecule expression and interleukin-6 (IL-6) and 6-keto-prostaglandin F(1α) (6-keto- PGF(1α)) secretion. Results. The affinity-purified IgG and the MAb with anti-β2GPI activity, but not the respective controls, displayed EC binding, which declined on cells incubated in serum-free medium and was restored in a dose-dependent manner by exogenous human β2GPI. After EC binding, both polyclonal and monoclonal antibodies up-regulated adhesion molecule expression. Anti-β2GPI MAb also significantly increased IL-6 and 6-keto- PGF(1α) secretion. Conclusion. These findings support the hypothesis that anti-β2GPI antibodies bind and activate EC through the adherent cofactor β2GPI, likely leading to a procoagulant state.

AB - Objective. To investigate the ability of human anti-β2-glycoprotein I (anti-β2GPI) antibodies to recognize the cofactor adherent on endothelial cells (EC) and to modulate endothelial functions. Methods. Six human affinity-purified polyclonal anti-β2GPI IgG and 2 IgM monoclonal antibodies (MAb) were obtained from patients with the antiphospholipid syndrome. The antibodies were tested for their ability to 1) bind to endothelial monolayers through the adherent β2GPI and 2) modulate endothelial adhesion molecule expression and interleukin-6 (IL-6) and 6-keto-prostaglandin F(1α) (6-keto- PGF(1α)) secretion. Results. The affinity-purified IgG and the MAb with anti-β2GPI activity, but not the respective controls, displayed EC binding, which declined on cells incubated in serum-free medium and was restored in a dose-dependent manner by exogenous human β2GPI. After EC binding, both polyclonal and monoclonal antibodies up-regulated adhesion molecule expression. Anti-β2GPI MAb also significantly increased IL-6 and 6-keto- PGF(1α) secretion. Conclusion. These findings support the hypothesis that anti-β2GPI antibodies bind and activate EC through the adherent cofactor β2GPI, likely leading to a procoagulant state.

UR - http://www.scopus.com/inward/record.url?scp=0030897237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030897237&partnerID=8YFLogxK

U2 - 10.1002/art.1780400322

DO - 10.1002/art.1780400322

M3 - Article

VL - 40

SP - 551

EP - 561

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 3

ER -